Skip to content

Geron GERN Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

Immunome logo
ImmunomeIMNM
Arcus Biosciences logo
Arcus BiosciencesRCUS
Tango Therapeutics logo
Tango TherapeuticsTNGX
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's operating lease right-of-use asset amortization?
Geron (GERN) reported operating lease right-of-use asset amortization of $192K in Q1 2026.
How has Geron's operating lease right-of-use asset amortization changed year-over-year?
Geron's operating lease right-of-use asset amortization increased by 8.5% year-over-year, from $177K to $192K.
What is the long-term trend for Geron's operating lease right-of-use asset amortization?
Over 4 years (2021 to 2025), Geron's operating lease right-of-use asset amortization has grown at a 6.5% compound annual growth rate (CAGR), from $568K to $730K.